infliximab

1. Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis.
   疾病活动度，ANCA，IL23R基因型状态决定了溃疡性结肠炎病人对英夫利昔单抗的早期应答。
2. Overall, the researchers conclude that maintenance infliximab therapy provided a better patient response than did as-needed therapy.
   研究者总结到，英夫利昔持续治疗银屑病产生的治疗效果要好于按需治疗。
3. Methods: Using sterilized water for injection to dissolve infliximab injection, to avoid foaming during the process of dispensing and to use it right after it was ready.
   用注射用水溶解英夫利西单抗，配制时防止泡沫产生，现配现用；
4. Moreover, infliximab use did not increase the proportion of patients who were able to taper their steroid dosages without relapse.
   另外，使用英夫利昔单抗不会增加减少类固醇用量而不复发的患者比率。
5. Infliximab, a chimeric IgG1 kappa monoclonal antibody against TNF-alpha, has been effective in the treatment of enteric as well as fistulous complications of Crohn's disease.
   目前已经证实，英夫利昔单抗（一种抗TNF-α的嵌合IgG1κ单克隆抗体）用于克罗恩病肠道并发症的治疗，与其治疗克罗恩病瘘管并发症一样有效。
6. OBJECTIVE: To evaluate the efficacy and the safety of infliximab for the treatment of the diseases of digestive system.
   目的：评价英利昔单抗在消化系统相关疾病治疗中的疗效和安全性。
7. OBJECTIVE: To determine potential differences in clinical responses, soluble drug levels and antibody formation between patients with RA receiving infliximab and adalimumab.
   目的：研究接受英夫利西单抗和阿达木单抗治疗的风湿性关节炎患者，确定他们之间的临床反应、溶解药物浓度以及抗体形成的差异。
8. Results: In all3 patients, dilation of a colonic stricture was accomplished by injection of infliximab, via the sclerotherapy technique, into the distal and medial portions of the stricture.
   结果：通过硬化治疗技术，在肠管狭窄区的远端和中间部分注射英夫利昔单抗，全部3名患者的结肠狭窄都得到了扩张。
9. The therapeutic effect observation and nursing for patients with rheumatic arthritis treated by infliximab
   英芙利昔单抗治疗类风湿关节炎的疗效观察及护理
10. Conclusions: Infliximab was shown to be effective in the treatment of strictures in3 patients.
    结论：英夫利昔单抗在3名患者的肠腔狭窄治疗中有效果。
11. Clinical experience in the treatment of Crohn'disease with infliximab
    英夫利西单抗治疗克罗恩病3例报道
12. The Efficacy and Safety of Infliximab in the Treatment of Ulcerative Colitis: A Meta-analysis
    英夫利昔治疗溃疡性结肠炎疗效与安全性的meta分析
13. Background The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown.
    背景在克罗恩病患者中，英夫利西单抗和硫唑嘌呤单药治疗或联合治疗的相对疗效和安全性尚未被了解。
14. Nursing Care for Patients with Juvenile Idiopathic Arthritis Managed with Infliximab Therapy "English Opening, Sicilian Reversed"
    英夫利西单抗靶向治疗幼年特发性关节炎患儿的护理
15. Infliximab and etanercept considered individually also were not associated with a risk of lymphoma.
    英利昔单抗和依那西普分别使用与患淋巴瘤风险间也无相关关系。
16. Therapeutic effect of infliximab on ulcerative colitis model of rat
    英夫利西单抗对溃疡性结肠炎模型大鼠的治疗作用
17. The introduction of the first anti-TNF drug, infliximab ( Remicade), revolutionized the treatment of Crohn's disease, wrote Dr.
    英夫利昔单抗（Remicade）是第一种抗-TNF药物，它的出现是克罗恩病治疗的一次革命。
18. Efficacy of infliximab in treatment of Crohn's disease with short-bowel syndrome: one case report
    英夫利西单抗治疗顽固性克罗恩病并短肠综合征1例
19. Although the TREAT registry has shown systemic infliximab to be safe in the long term, there is concern regarding infectious as well as neoplastic complications.
    虽然，TREAT登记处已经指出，从长期观察来看，全身性应用英夫利昔单抗是安全的，但要关注发生肿瘤以及感染性并发症。
20. Objective To assess the clinical effects of infliximab in experimental immune myositis ( EIM).
    目的观察英夫利昔对实验性免疫性肌炎（EIM）的治疗效果。
21. Local injection of infliximab in the postoperative recurrence of Crohn's disease
    局部注射英夫利昔单抗治疗克罗恩病的术后复发
22. Infliximab for severe, treatment-resistant psoriasis: A prospective, open-label study
    英夫利昔单抗治疗重度、难治性银屑病：一项前瞻性、开放标记研究
23. Fecal lactoferrin: A new parameter to monitor infliximab therapy
    粪乳铁蛋白：一种监测英利昔单抗治疗的新指标
24. Infliximab for induction and maintenance therapy for ulcerative colitis
    英夫利昔单抗对溃疡性结肠炎的诱导与维持治疗作用
25. Programmed cell death of keratinocytes in infliximab treated plaque-type psoriasis
    英夫利昔单抗治疗的斑块型银屑病中的角质形成细胞凋亡
26. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase ⅲ, multicentre, double-blind trial
    英夫利昔单抗诱导和维持治疗中重度银屑病的Ⅲ期临床多中心双盲对照试验
27. To assess the clinical effects of infliximab ( anti-TNF-a monoclonal antibody) in experimental autoimmune myositis.
    观察英夫利昔（抗肿瘤坏死因子单克隆抗体，infliximab）对实验性自身免疫性肌炎的疗效；
28. Infliximab is an IgG1 monoclonal antibody ( a chimera of human constant and mouse variable regions).
    Infliximab是针对TNF的特异性IgG1单克隆抗体（由人Ig稳定区和鼠Ig可变区组成的嵌合体）；
29. Infliximab can increase IL-10 content by reducing TNF-α content in tissue, consequently control development of inflammation, lysis clinical symptoms of rats with colitis, and can provide certain experimental evidence for clinical treatment of Ulcerative colitis.
    英夫利西单抗可以通过降低组织中TNF-α的含量，提高IL-10的含量，控制炎症的进展，缓解结肠炎大鼠的临床症状，能够为临床治疗溃疡性结肠炎提供一定的实验依据。
30. It demonstrates that there is better efficacy of Infliximab.
    说明英夫利西单抗对大鼠结肠炎有较好疗效。

noun

1. an anti-TNF compound (trade name Remicade) consisting of an antibody directed against TNF

   Synonym:    Remicade

2. a monoclonal antibody (trade name Remicade) used to treat Crohn's disease and rheumatoid arthritis

   Synonym:    Remicade